comparemela.com

Es Sclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Second-Line Sacituzumab Govitecan Elicits Responses, Provides Disease Control in ES-SCLC

Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

United statesAfshin dowlatiRoberth griesThoracic scientific team at university hospitalsJazz pharmaceuticalsCancer drug development at university hospitalsDepartment of medicine division hematologySchool of medicineGilead sciencesCleveland medical centerMedicine divisionDevelopmental therapeutics programCase comprehensive cancer centerEndowed directorCancer drug developmentUniversity hospitals

FDA Awards Orphan Drug Designation to Alisertib in ES-SCLC

The FDA has granted an orphan drug designation to alisertib (MLN8237) for the treatment of patients with extensive-stage small cell lung cancer.

Alanh auerbachPuma biotechnologySmall cell lungOrphan drug designationSmall cell lung cancerExtensive stage small cell lung cancerEs sclcPuma ali 4201 trial

The Evolving Treatment Landscape of Small Cell Lung Cancer

Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.

Christian grohLaurent greillerEvolving paradigmsEvolving treatment landscapeSmall cell lungSmall cell lung cancerLimited stage sclcExtensive stage sclcLs sclcEs sclcNovel therapyCombination therapyClinical trialsBispecific therapyBispecific antibodiesAdverse events

Clinical Data With Lurbinectedin in Small Cell Lung Cancer

Key opinion leaders share a focused discussion on lurbinectedin and its evolving role in small cell lung cancer following frontline therapy.

Evolving paradigmsData with lurbinectedinSmall cell lungSmall cell lung cancerLimited stage sclcExtensive stage sclcLs sclcEs sclcSecond line therapySecond line treatmentImforte trialImforte studyPlatinum resistantPlatinum sensitiveMaintenance therapyAdverse events

Small Cell Lung Cancer: What is the Role of IO Therapy in the Frontline Setting?

A brief review of the role that immunotherapy agents play in the frontline management of patients with small cell lung cancer.

Evolving paradigmsCell lung cancerSmall cell lung cancerLimited stage sclcExtensive stage sclcLs sclcEs sclcFirst line treatmentFrontline treatmentFirst line therapyFrontline therapyChemo ioTrio therapyCombination therapyNivo ipiIpi nivo

vimarsana © 2020. All Rights Reserved.